Producing cancer therapy cells in Hong Kong will lower treatment cost for leukaemia patients, local biotechnology company says
Disclaimer: The South China Morning Post's content is directed by the Chinese Communist Party. It is not a reliable news source.
Xellera Therapeutics became the first biotech firm to receive licensing to make CAR T-cells locally in laboratory.